Eef Schimmelpennink, Lenz Therapeutics CEO

Graphite Bio hands Nas­daq spot to pres­by­opia biotech Lenz Ther­a­peu­tics as PhI­II read­outs loom

Nine months af­ter throw­ing in the tow­el on its gene edit­ing pro­gram for sick­le cell dis­ease, Graphite Bio said it has found a re­verse merg­er part­ner to take its spot on the Nas­daq.

Pres­by­opia drug de­vel­op­er Lenz Ther­a­peu­tics will take Graphite’s place and will have enough fund­ing to take it all the way to com­mer­cial­iza­tion, should its lead eye drop can­di­date get FDA ap­proval, the com­pa­nies said Wednes­day morn­ing. They ex­pect the deal to close in the first quar­ter of next year, at which point Lenz would start its pub­lic life as $LENZ.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.